Trial Profile
Double-blind, randomized, placebo controlled trial to study efficacy of pegfilgrastim in reduction of risk of Febrile Neutropenia in early breast cancer Japanese patients
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 19 Mar 2020
Price :
$35
*
At a glance
- Drugs Pegfilgrastim (Primary) ; Cyclophosphamide; Docetaxel
- Indications Febrile neutropenia
- Focus Therapeutic Use
- Sponsors Kyowa Hakko Kirin
- 21 Oct 2015 New trial record